Azenta, Inc. (AZTA): Business Model Canvas

In der dynamischen Landschaft der wissenschaftlichen Innovation entwickelt sich Azenta, Inc. (AZTA) zu einem Kraftpaket technologischer Präzision, das die komplexen Welten der Biowissenschaften und der Halbleitertechnologien strategisch verbindet. Mit einem komplexen Geschäftsmodell, das Spitzenforschung, fortschrittliche Fertigung und Speziallösungen miteinander verbindet, verwandelt Azenta wissenschaftliche Herausforderungen in bahnbrechende Chancen in den Bereichen Pharmazie, Biotechnologie und Forschung. Ihr einzigartiger Ansatz kombiniert hochentwickelte kryogene Speichersysteme, hochpräzise Ausrüstung und ein starkes Engagement für den technologischen Fortschritt, der sie auf einem sich schnell entwickelnden globalen Markt auszeichnet.

Azenta, Inc. (AZTA) – Geschäftsmodell: Wichtige Partnerschaften

Strategische Kooperationen mit Life-Science-Forschungseinrichtungen

Azenta, Inc. unterhält strategische Partnerschaften mit folgenden Forschungseinrichtungen:

Forschungseinrichtung	Partnerschaftsfokus	Gründungsjahr
Harvard Medical School	Fortschrittliche Bioverarbeitungstechnologien	2022
MIT Whitehead Institute	Lösungen für die Verwaltung genomischer Proben	2021

Partnerschaften mit Pharma- und Biotechnologieunternehmen

Zu den wichtigsten Partnerschaften im Pharma- und Biotechnologiebereich gehören:

• Pfizer Inc. – Kollaboratives Probenmanagement und Logistik
• Moderna Therapeutics – Fortschrittliche Biorepository-Lösungen
• Bristol Myers Squibb – Präzise Kühlkettentechnologien

Lieferantenbeziehungen mit Herstellern fortschrittlicher Materialien und Ausrüstung

Kritische Lieferantenbeziehungen umfassen:

Lieferant	Angebotskategorie	Jährlicher Vertragswert
Thermo Fisher Scientific	Laborausrüstung	12,5 Millionen US-Dollar
Corning Incorporated	Fortschrittliche Materialien	8,3 Millionen US-Dollar

Allianzen mit akademischen Forschungszentren und Universitäten

Bedeutende akademische Forschungskooperationen:

• Stanford University – Forschungskooperation im Bioingenieurwesen
• Johns Hopkins University – Probenmanagement für Präzisionsmedizin
• University of California, San Francisco – Entwicklung der Genomtechnologie

Azenta, Inc. (AZTA) – Geschäftsmodell: Hauptaktivitäten

Design und Herstellung von Life-Science- und Halbleitergeräten

Im Geschäftsjahr 2023 meldete Azenta einen Geräteumsatz von 340,7 Millionen US-Dollar, wobei der Schwerpunkt auf spezialisierten Herstellungsprozessen lag.

Ausrüstungskategorie	Jährliches Produktionsvolumen	Produktionsstandorte
Life-Science-Ausrüstung	1.200 Einheiten	Woburn, MA und Shanghai, China
Halbleiterausrüstung	850 Einheiten	Billerica, MA

Lösungen für die Verwaltung und Lagerung kryogener Proben

Azenta betreibt acht globale Biorepository-Einrichtungen mit einer Gesamtlagerkapazität von über 500 Millionen biologischen Proben.

• Kryo-Lagersysteme in 42 Ländern im Einsatz
• Jährlicher Umsatz mit Probenverwaltungsdiensten: 127,5 Millionen US-Dollar
• Über 3.500 Forschungseinrichtungen und Pharmaunternehmen wurden bedient

Forschung und Entwicklung fortschrittlicher Technologien

Die F&E-Investitionen für das Geschäftsjahr 2023 beliefen sich auf 62,4 Millionen US-Dollar, was 11,6 % des Gesamtumsatzes des Unternehmens entspricht.

F&E-Schwerpunktbereich	Patentanmeldungen	Aktive Forschungsprojekte
Kryo-Technologien	23	12
Halbleiterverarbeitung	18	9

Feinmechanik und Fertigungsprozesse

Fertigungstoleranz: ±0,001 mm über kritische Gerätekomponenten hinweg.

• Nach ISO 9001:2015 zertifizierte Produktionsstätten
• Durchschnittliche Herstellungszykluszeit: 6–8 Wochen
• Ablehnungsrate bei der Qualitätskontrolle: Weniger als 0,5 %

Globale Vertriebs- und Kundensupportdienste

Weltweite Vertriebsabdeckung auf 6 Kontinenten mit 247 engagierten Vertriebs- und Supportmitarbeitern.

Region	Vertriebsmitarbeiter	Jährliche Kundensupport-Stunden
Nordamerika	98	42,500
Europa	67	29,300
Asien-Pazifik	82	36,800

Azenta, Inc. (AZTA) – Geschäftsmodell: Schlüsselressourcen

Spezialisierte Ingenieurskunst und technisches Fachwissen

Azenta, Inc. unterhält ein hochspezialisiertes technisches Personal mit folgender Zusammensetzung:

Mitarbeiterkategorie	Anzahl der Mitarbeiter
Gesamtes F&E-Personal	387
Wissenschaftler auf Doktorgradniveau	129
Ingenieursspezialisten	258

Fortschrittliche Produktionsanlagen

Azenta betreibt mehrere Produktionsstätten mit den folgenden Spezifikationen:

• Gesamtzahl der Produktionsstandorte: 6
• Primäre Produktionsregionen: USA, China, Singapur
• Gesamtfläche der Produktionsfläche: 275.000 Quadratfuß

Proprietäre Technologien

Kategorie „Technologie“.	Anzahl proprietärer Technologien
Kryo-Speichertechnologien	17
Halbleiterausrüstungstechnologien	23
Automatisierungstechnologien für Biowissenschaften	12

Portfolio für geistiges Eigentum

Zu den geistigen Eigentumswerten von Azenta gehören:

• Gesamtzahl der aktiven Patente: 142
• Ausstehende Patentanmeldungen: 38
• Patentfamilien: 56

Qualifizierte Arbeitskräfte

Zusammensetzung der Belegschaft	Anzahl der Mitarbeiter
Gesamtzahl der Mitarbeiter	1,643
Inhaber fortgeschrittener Abschlüsse	412
Technische Spezialisten	987

Azenta, Inc. (AZTA) – Geschäftsmodell: Wertversprechen

Hochpräzise wissenschaftliche Geräte für Forschung und klinische Anwendungen

Azenta bietet wissenschaftliche Geräte mit folgenden Spezifikationen an:

Gerätetyp	Präzisionsniveau	Marktsegment
Kryospeichersysteme	±0,1°C Genauigkeit	Biorepositorium
Beispielverwaltungsplattformen	99,9 % Tracking-Zuverlässigkeit	Forschungslabore
Werkzeuge zur Halbleiterfertigung	Präzision im Nanometerbereich	Hightech-Fertigung

Innovative Probenmanagementlösungen für die Biowissenschaften

Zu den Probenverwaltungslösungen von Azenta gehören:

• Automatisierte Probenverfolgungssysteme
• Kryo-Speicherinfrastruktur
• End-to-End-Probenverwaltungsplattformen

Fortschrittliche Halbleiterfertigungstechnologien

Angebote im Bereich Halbleitertechnologie:

Technologie	Leistungsmetrik	Marktanwendung
Wafer-Handhabungssysteme	Kompatibilität mit 300-mm-Wafern	Halbleiterproduktion
Präzisionsausrichtungswerkzeuge	Positionierung im Submikrometerbereich	Fortschrittliche Chipherstellung

Zuverlässige und skalierbare kryogene Speichersysteme

Möglichkeiten der kryogenen Lagerung:

• Speicherkapazität: Bis zu 10 Millionen biologische Proben
• Temperaturbereich: -190 °C bis +37 °C
• Erhaltungsrate der Probenintegrität: 99,99 %

Modernste technologische Lösungen für komplexe wissenschaftliche Herausforderungen

Metriken für Technologielösungen:

Lösungskategorie	Technologische Leistungsfähigkeit	Auswirkungen auf den Markt
Automatisierung der Biowissenschaften	KI-gesteuertes Probenmanagement	Verbesserung der Forschungseffizienz
Halbleiterverarbeitung	Erweiterte Materialhandhabung	Verbesserung der Fertigungspräzision

Azenta, Inc. (AZTA) – Geschäftsmodell: Kundenbeziehungen

Direktvertriebsunterstützung und technische Beratung

Azenta bietet Direktvertriebsunterstützung durch ein engagiertes Team von 87 Vertriebsprofis (Stand Q4 2023). Das Unternehmen meldete für das Geschäftsjahr 2023 einen Gesamtumsatz von 524,7 Millionen US-Dollar, wobei spezialisierte technische Beratungsdienste in mehrere Geschäftsbereiche integriert sind.

Kundensupport-Metrik	Daten für 2023
Gesamtzahl der Vertriebsmitarbeiter	87
Durchschnittliche Kundeninteraktionszeit	2,3 Stunden pro Beratung
Reaktionszeit des technischen Supports	4,1 Stunden

Laufende Kundenschulungs- und Schulungsprogramme

Azenta bietet umfassende Schulungsprogramme für die Märkte Life Sciences und Halbleiterausrüstung an.

• Jährliche Schulungen: 42 Workshops
• Online-Trainingsmodule: 26 digitale Kurse
• Zertifizierte Schulungsteilnehmer: 1.284 im Jahr 2023

Persönlicher Service für Forschungs- und Industriekunden

Das Unternehmen betreut 1.356 Forschungseinrichtungen und Industriekunden maßgeschneiderte Lösungspakete.

Kundensegment	Anzahl der Kunden	Anpassungsebene
Forschungseinrichtungen	782	Hoch
Industriekunden	574	Mittel bis Hoch

Langfristiger Partnerschaftsansatz

Azenta weist in seinen Geschäftsbereichen eine durchschnittliche Kundenbindungsrate von 89,6 % auf, wobei 73 Kunden über eine Partnerschaft von mehr als 10 Jahren verfügen.

Reaktionsschneller technischer Support und Wartungsdienste

Die technische Support-Infrastruktur umfasst 132 engagierte Support-Techniker mit globaler Abdeckung.

• Globale Supportzentren: 7 Standorte
• Technischer Support rund um die Uhr verfügbar
• Durchschnittliche Geräteverfügbarkeit: 97,3 %

Support-Metrik	Leistung
Total-Support-Ingenieure	132
Globale Supportzentren	7
Jährliche Support-Interaktionen	4,672

Azenta, Inc. (AZTA) – Geschäftsmodell: Kanäle

Direktvertriebsteam

Ab 2024 unterhält Azenta ein engagiertes Direktvertriebsteam von etwa 215 Vertriebsprofis auf den globalen Märkten. Das Vertriebsteam konzentriert sich auf die Branchen Life Sciences, Halbleiter und fortschrittliche Materialien.

Vertriebsregion	Anzahl der Vertriebsmitarbeiter
Nordamerika	95
Europa	65
Asien-Pazifik	55

Online-E-Commerce-Plattformen

Azenta betreibt mehrere digitale Vertriebskanäle mit einem jährlichen Online-Transaktionsvolumen von 87,3 Millionen US-Dollar im Jahr 2023.

• Unternehmenswebsite (Direktvertriebsportal)
• Spezialisierte Marktplätze für wissenschaftliche Geräte
• Digitale Beschaffungsplattformen

Wissenschaftliche Konferenzen und Messen

Azenta nimmt jährlich an 42 internationalen wissenschaftlichen und technologischen Konferenzen teil, wobei die Marketingausgaben auf 2,4 Millionen US-Dollar geschätzt werden.

Vertriebsnetzwerke

Das Unternehmen unterhält Partnerschaften mit 87 globalen Vertriebshändlern für wissenschaftliche Geräte in 23 Ländern.

Region	Anzahl der Vertriebspartner
Nordamerika	28
Europa	32
Asien-Pazifik	27

Digitales Marketing und technische Kommunikationskanäle

Azenta nutzt mehrere digitale Kommunikationsplattformen mit den folgenden Engagement-Kennzahlen:

• LinkedIn-Follower: 45.670
• Twitter-Follower: 22.340
• Teilnehmer des technischen Webinars (2023): 3.850
• Jährliches Budget für digitales Marketing: 1,7 Millionen US-Dollar

Azenta, Inc. (AZTA) – Geschäftsmodell: Kundensegmente

Pharmazeutische Forschungsorganisationen

Azenta beliefert pharmazeutische Forschungsorganisationen mit wichtigen Life-Science-Lösungen. Im Jahr 2023 wurde der globale Pharmaforschungsmarkt auf 179,4 Milliarden US-Dollar geschätzt.

Kundentyp	Geschätzte Marktgröße	Penetrationsrate
Top 20 Pharmaunternehmen	98,6 Milliarden US-Dollar	54.9%
Mittelgroße pharmazeutische Forschungsorganisationen	52,3 Milliarden US-Dollar	29.1%

Biotechnologieunternehmen

Biotechnologieunternehmen stellen ein bedeutendes Kundensegment für die Life-Science-Technologien von Azenta dar.

• Größe des globalen Biotechnologiemarktes im Jahr 2023: 627,2 Milliarden US-Dollar
• Anzahl aktiver Biotechnologieunternehmen weltweit: 8.442
• Geschätzte F&E-Ausgaben: 186,3 Milliarden US-Dollar pro Jahr

Akademische und staatliche Forschungseinrichtungen

Azenta bietet Forschungseinrichtungen spezielle Ausrüstung und Dienstleistungen an.

Institutionstyp	Anzahl potenzieller Kunden	Jährliches Forschungsbudget
Top 100 Forschungsuniversitäten	100	68,4 Milliarden US-Dollar
Staatliche Forschungslabore	237	45,7 Milliarden US-Dollar

Halbleiterhersteller

Die Halbleiterfertigung stellt für Azenta ein wachsendes Kundensegment dar.

• Weltweite Halbleitermarktgröße im Jahr 2023: 573,4 Milliarden US-Dollar
• Anzahl aktiver Halbleiterhersteller: 332
• Geschätzte Investitionsausgaben: 89,6 Milliarden US-Dollar

Gesundheitswesen und klinische Labore

Klinische Labore stellen ein wichtiges Kundensegment für die Diagnoselösungen von Azenta dar.

Labortyp	Gesamtzahl	Jährliches Testvolumen
Klinische Diagnoselabore	6,773	8,2 Milliarden Tests jährlich
Krankenhausbasierte Labore	5,534	4,7 Milliarden Tests jährlich

Azenta, Inc. (AZTA) – Geschäftsmodell: Kostenstruktur

Forschungs- und Entwicklungsinvestitionen

Für das Geschäftsjahr 2023 meldete Azenta, Inc. Forschungs- und Entwicklungskosten in Höhe von 91,4 Millionen US-Dollar, was 13,4 % des Gesamtumsatzes entspricht.

Geschäftsjahr	F&E-Ausgaben	Prozentsatz des Umsatzes
2023	91,4 Millionen US-Dollar	13.4%
2022	83,2 Millionen US-Dollar	12.9%

Herstellungs- und Produktionskosten

Die gesamten Herstellungskosten für Azenta beliefen sich im Jahr 2023 auf 237,6 Millionen US-Dollar, wobei sich die wesentlichen Bestandteile wie folgt aufschlüsseln:

• Direkte Arbeitskosten: 68,3 Millionen US-Dollar
• Rohstoffkosten: 112,5 Millionen US-Dollar
• Fertigungsaufwand: 56,8 Millionen US-Dollar

Globale Vertriebs- und Marketingaktivitäten

Die Vertriebs- und Marketingausgaben für Azenta beliefen sich im Geschäftsjahr 2023 auf insgesamt 129,7 Millionen US-Dollar.

Geografische Region	Marketingausgaben
Nordamerika	62,4 Millionen US-Dollar
Europa	37,2 Millionen US-Dollar
Asien-Pazifik	30,1 Millionen US-Dollar

Wartung der Technologieinfrastruktur

Die Wartungskosten für Technologie und Infrastruktur beliefen sich im Jahr 2023 auf 45,6 Millionen US-Dollar, darunter:

• IT-System-Upgrades: 22,3 Millionen US-Dollar
• Investitionen in Cybersicherheit: 12,5 Millionen US-Dollar
• Cloud-Infrastruktur: 10,8 Millionen US-Dollar

Talentakquise und -bindung

Die Personal- und Talentkosten beliefen sich im Jahr 2023 auf 96,2 Millionen US-Dollar.

Ausgabenkategorie	Betrag
Gehälter und Löhne	76,5 Millionen US-Dollar
Leistungen an Arbeitnehmer	15,3 Millionen US-Dollar
Rekrutierung und Schulung	4,4 Millionen US-Dollar

Azenta, Inc. (AZTA) – Geschäftsmodell: Einnahmequellen

Geräteverkauf im Life-Science-Sektor

Für das Geschäftsjahr 2023 meldete Azenta einen Umsatz mit Life-Science-Geräten in Höhe von 281,4 Millionen US-Dollar.

Produktkategorie	Umsatz (Mio. USD)	Prozentsatz der Gesamtsumme
Automatisierte Probenverwaltungssysteme	156.7	55.7%
Ausrüstung für die Genomforschung	124.6	44.3%

Halbleiterausrüstungslösungen

Halbleiterausrüstungslösungen erwirtschafteten im Geschäftsjahr 2023 einen Umsatz von 202,3 Millionen US-Dollar.

Halbleitersegment	Umsatz (Mio. USD)
Fortschrittliche Verpackungsausrüstung	112.5
Halbleitertestlösungen	89.8

Umsatz mit kryogenen Probenspeichersystemen

Kryospeichersysteme trugen im Jahr 2023 97,6 Millionen US-Dollar zum Gesamtumsatz von Azenta bei.

• Biorepository-Speicherlösungen: 62,3 Millionen US-Dollar
• Forschungsinstitutionelle kryogene Systeme: 35,3 Millionen US-Dollar

Laufende Wartungs- und Serviceverträge

Service- und Wartungsverträge generierten im Geschäftsjahr 2023 wiederkehrende Einnahmen in Höhe von 73,8 Millionen US-Dollar.

Servicetyp	Jährlicher Vertragswert (Mio. USD)
Gerätewartung	48.5
Technische Supportverträge	25.3

Technologielizenzierung und Beratungsdienste

Technologielizenzierungs- und Beratungsdienstleistungen machten im Jahr 2023 einen Umsatz von 41,2 Millionen US-Dollar aus.

• Lizenzierung von geistigem Eigentum: 24,7 Millionen US-Dollar
• Beratungsleistungen: 16,5 Millionen US-Dollar

Gesamtjahresumsatz (2023): 696,3 Millionen US-Dollar

Azenta, Inc. (AZTA) - Canvas Business Model: Value Propositions

You're looking at the core reasons why pharmaceutical and biotech clients choose Azenta, Inc. for their critical research infrastructure. It's about de-risking their most valuable assets-their biological samples-and speeding up their R&D timelines. The numbers show where the business is focused.

Flawless sample integrity via automated cold-chain management.

This value proposition is anchored in the Sample Management Solutions (SMS) segment, which provides the physical and logistical backbone for sample preservation. The focus here is on reliability at scale, which is essential for multi-year clinical trials and biobanking efforts. The company's ability to maintain viability across ultra-low temperatures is non-negotiable for customers.

The financial contribution from this area for the full fiscal year 2025 was substantial:

Metric	Amount/Value
Full Year Fiscal 2025 SMS Revenue	$325 million
Q3 Fiscal 2025 SMS Revenue	$78 million
Q4 Fiscal 2025 SMS Revenue	$86 million

The Q3 2025 revenue for SMS was down 4% year-over-year, but Q4 saw a rebound with 2% reported growth, showing the lumpy nature of capital equipment sales like Automated Stores.

Accelerating drug discovery with high-throughput multiomics services.

The Multiomics segment is the growth engine, providing the analytical horsepower needed to turn stored samples into actionable data. This includes Next Generation Sequencing (NGS), which has been a consistent performer.

• NGS volume growth was at double-digit rates in Q2 2025.
• NGS pricing showed stabilization for the 4th consecutive quarter as of Q2 2025.
• Q3 Fiscal 2025 Multiomics Revenue was $66 million, up 4% year-over-year.
• Full Year Fiscal 2025 Multiomics Revenue was $269 million, up 6% year-over-year.

This segment's performance is key to the overall organic growth trajectory. For the full year 2025, Azenta, Inc.'s total organic revenue grew 3%.

End-to-end sample lifecycle management for complex therapies.

This value is the sum of both segments, supported by a strong balance sheet to ensure continuity of service, which is critical when managing samples for advanced cell and gene therapies. The company ended fiscal year 2025 with a total balance of cash, cash equivalents, and marketable securities of $546 million.

The overall financial results for the full fiscal year 2025 reflect this integrated approach:

• Full Year Fiscal 2025 Total Revenue: $594 million.
• Full Year Fiscal 2025 Adjusted EBITDA Margin: 11.2%, an improvement of 310 basis points year-over-year.
• Full Year Fiscal 2025 Non-GAAP Diluted EPS: $0.51.

The margin expansion, up 310 basis points for the year, shows the value of operational efficiencies being realized across the entire lifecycle management process.

Reduced time and cost to lead candidates in gene therapy.

Azenta, Inc. directly addresses the timeline and safety concerns in gene therapy development through strategic integrations. For instance, a partnership launched in May 2025 integrates their sequencing capabilities with Form Bio's computational solutions to provide AAV Genome Integrity Characterization using their LAAVA software.

This collaboration is designed to streamline lead candidate selection by providing data-driven insights into AAV capsid contents, aiming to enhance therapeutic safety and manufacturability, which directly translates to reduced development timelines and costs for gene therapy developers.

Enterprise-wide sample intelligence software and informatics.

The informatics layer, which includes software like Freezer Pro and Limfinity, transforms raw sample data into intelligence. This software underpins the reliability of the entire cold-chain service, ensuring data integrity matches sample integrity. While specific revenue for informatics is bundled, the focus on operational improvements across the board supports this value.

The company's commitment to operational excellence is evident in its profitability metrics, which are a direct result of better system utilization and cost execution:

Metric (Continuing Operations)	Q3 Fiscal 2025	Q4 Fiscal 2025
Adjusted EBITDA Margin	12.3%	13%
Non-GAAP Diluted EPS	$0.19	$0.21

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Customer Relationships

You're looking at how Azenta, Inc. (AZTA) structures its interactions across its diverse product and service offerings as of late 2025. The approach is definitely segmented based on the value and complexity of the offering.

For high-value systems, like the Automated Stores and Cryogenic Systems, Azenta, Inc. relies on a dedicated direct sales force. This team manages the complex sales cycle for these capital equipment and the associated storage services. Management noted in their Q4 2025 update that they took decisive steps to reshape the commercial organization, including an expanded field presence, to sharpen go-to-market targeting for fiscal 2025.

The Sample Repository Services (SRS), a key part of the Sample Management Solutions (SMS) segment, necessitates consultative, long-term relationships. These services are foundational to the trust required for long-term sample custody. The revenue performance of this segment, which includes SRS, shows its scale:

Period Ended	Sample Management Solutions Revenue (Millions USD)	Year-over-Year Change
March 31, 2025 (Q2 FY25)	$80	8% increase
June 30, 2025 (Q3 FY25)	$78	4% decrease
September 30, 2025 (Q4 FY25)	$86	2% increase

For consumables and standard services, the relationship leans toward self-service and e-commerce channels. These are the more transactional elements of the business. The growth in these areas, specifically for Consumables and Instruments, was noted as a meaningful contributor to the Q4 2025 results.

Support for the installed base of systems is managed through technical support and service contracts. This ensures uptime and continued use of their hardware and software platforms, such as Freezer Pro and Limfinity. The SMS segment also reports revenue from Product Services, which falls under this relationship type.

Azenta, Inc. maintains definitely collaborative relationships with top pharma, as they provide services to the industry's top pharmaceutical, biotech, academic and healthcare institutions globally. This focus is critical, as the company's overall fiscal year 2025 revenue was $593.8 million, with 39% of that revenue generated outside the United States in fiscal year 2025, showing a growing international footprint with these key customers.

• The company ended the fiscal year 2025 with $546 million in cash, cash equivalents, and marketable securities.
• The debt-to-equity ratio stood at a low 0.03.
• The overall business achieved an Adjusted EBITDA Margin of 11.2% for the full fiscal year 2025.

Finance: review the Q1 2026 sales pipeline against the 3% to 5% organic growth guidance for the full year 2026 by end of January.

Azenta, Inc. (AZTA) - Canvas Business Model: Channels

You're looking at how Azenta, Inc. (AZTA) gets its Sample Management Solutions and Multiomics services into the hands of pharmaceutical and biotech clients as of late 2025. The channels reflect a hybrid approach, mixing direct engagement for high-value services with broader distribution for core products.

The direct sales force targets the two core continuing operations segments. For the third quarter of fiscal year 2025, the Sample Management Solutions segment generated $78 million in revenue, while the Multiomics segment brought in $66 million. The direct team is essential for selling complex, automated cold-chain infrastructure and high-throughput genomic services.

For core products, Azenta, Inc. relies on a trusted network of third-party distributors globally. While the exact number of partners isn't public, this channel helps extend reach for products like consumables and instruments, which contributed to the Sample Management Solutions revenue decline of 4% year-over-year in Q3 fiscal 2025.

The company-owned biorepository and service centers form a critical physical channel, ensuring sample integrity and local access. As of the June 30, 2025, balance sheet date, Azenta, Inc. maintained a cash and liquidity balance of $565 million, supporting this global footprint. The new biorepository in Greater Boston, for instance, is a 40,000 square foot facility.

Here is a look at the known physical channel locations supporting their operations:

Region	City/Site	Type of Facility Mentioned
North America	Burlington, MA	Corporate Headquarters
North America	Indianapolis, IN	Flagship Biorepository
North America	Waltham, MA	Multiomics Location
North America	Research Triangle Park, NC	Laboratory/Facility
North America	Seattle, WA	Laboratory/Facility
Europe	Leipzig, Germany	Laboratory/Facility
Europe	Oxford, United Kingdom	Laboratory/Facility

Investor relations and webcasts serve as the direct channel to the financial community. Management is focused on margin expansion, projecting 300 basis points of Adjusted EBITDA margin expansion for the full fiscal year 2025.

• Azenta Life Sciences Investor Day was scheduled for Wednesday, December 10, 2025, with the webcast presentation starting at 1:00 PM ET.
• The Q4 and Full Year Fiscal 2025 Earnings Conference Call and Webcast was scheduled for Friday, November 21, 2025, at 8:30 AM ET.
• The company's Market Capitalization as of November 21, 2025, was reported at $1.38 billion.

Digital platforms are key for the Multiomics business, which includes the GENEWIZ brand. GENEWIZ from Azenta Life Sciences provides services like Next Generation Sequencing and Gene Synthesis. While the platform facilitates ordering and payment, specific digital ordering volume or user statistics for fiscal 2025 aren't reported.

The digital channel is reinforced through strategic integrations, such as the partnership announced in May 2025 with Form Bio to enhance AAV gene therapy development through an integrated sequencing and data analysis solution. The overall Fiscal 2025 reported revenue was $593.82 million, with a reported loss of -$59.50 million.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Customer Segments

You're looking at the customer base for Azenta, Inc. as of late 2025, which is entirely focused on life sciences, having completed the strategic pivot away from semiconductor automation. The company's total revenue for the fiscal year ending September 30, 2025, reached $593.82M, with an organic growth rate of 3% for that full year. This revenue supports a global customer base, as 39% of total revenue was generated outside the United States in fiscal year 2025.

Azenta, Inc. serves its customers through two primary reporting segments: Sample Management Solutions (SMS) and Multiomics. These segments map directly to the essential needs of drug developers, researchers, and healthcare providers.

The Sample Management Solutions segment is the backbone for customers needing secure, long-term sample integrity. For instance, in the third quarter of fiscal year 2025, this segment generated $78 million in revenue, driven by services like Sample Repository Solutions and Core Products. In the fourth quarter, SMS revenue was $86 million, showing strength in areas like Clinical Biostores and Sample Storage, even with softness in Cryogenic Stores due to customer capital expenditure delays.

The Multiomics segment is the growth engine, focused on genomic services essential for modern therapy development. In the third quarter of fiscal year 2025, Multiomics revenue was $66 million, up 4% year-over-year, primarily fueled by Next Generation Sequencing. This segment directly supports advanced cell and gene therapy developers and large biotech firms needing high-throughput analysis.

Here's a quick look at the segment revenue performance from the third quarter of fiscal 2025, which gives you a clear picture of where the business was at that point:

Segment	Revenue (Q3 FY2025, in millions USD)	Year-over-Year Organic Growth (Q3 FY2025)
Sample Management Solutions	$78	-6%
Multiomics	$66	3%
Total Revenue (Continuing Operations)	$144	-2%

The customer segments are served by specific offerings within these structures. You're looking at a customer base that relies on Azenta, Inc. for mission-critical infrastructure and analysis.

• Top pharmaceutical and biotechnology companies use both segments for drug development pipelines.
• Academic and government research institutions are key users of Multiomics for discovery research.
• Clinical research organizations (CROs) and clinical trial sponsors rely heavily on Sample Management Solutions for trial material integrity.
• Advanced cell and gene therapy developers require Multiomics for sequencing and SMS for ultra-low temperature storage.
• Healthcare institutions and biobanks globally utilize Sample Repository Services and Clinical Biostores.

For the full year 2025, the company reported a strong cash position, ending the year with $283.5 million in cash, cash equivalents, and restricted cash, plus $262.7 million in marketable securities, ensuring they can continue to support these long-term customer relationships.

The Multiomics segment saw particular momentum, with organic revenue growing 10% year-over-year in the fourth quarter of fiscal 2025, driven by Next Generation Sequencing and Gene Synthesis, which are services directly tied to the most innovative drug development efforts.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Cost Structure

You're looking at the core expenses that drive Azenta, Inc.'s operations as of late 2025, focusing on the continuing businesses after the planned divestiture of B Medical Systems. The cost structure reflects a pivot toward high-tech services in Sample Management Solutions (SMS) and Multiomics.

Cost of revenue (COGS) for consumables and instruments is a primary driver. While specific 2025 COGS for consumables and instruments isn't fully itemized separately from the continuing operations' gross margin, we can infer the cost base from recent performance. For the third quarter of fiscal 2025, continuing operations generated revenue of $144 million, with an Adjusted Gross Margin of 48.5%. This implies an Adjusted Cost of Revenue of approximately $74.16 million for that quarter, which covers the direct costs associated with providing sample management products, consumables, and multiomics sequencing services. For context, the Total Cost of Revenue for the full fiscal year 2024 was $393 million on $656 million in total revenue, before the B Medical segment was classified as discontinued. The focus on higher-margin services within SMS and Multiomics is intended to improve this ratio.

Significant R&D investment for automation and multiomics expansion is managed with discipline. In the third quarter of fiscal 2025, Research and Development costs were lower year-over-year, contributing to a 6% decrease in total GAAP Operating Expenses compared to the prior year period. On a Non-GAAP basis for Q3 2025, Adjusted Operating Expense was $62 million, down 4% year-over-year, driven in part by lower R&D costs. This suggests a near-term focus on operational efficiency while maintaining necessary investment in automation for their Sample Management Solutions, such as automated stores and cryogenic systems, and expansion in Multiomics capabilities like Next Generation Sequencing.

Selling, General, and Administrative (SG&A) expenses for global sales are being tightly controlled as part of the transformation program. For Q3 2025, lower Selling, General, and Administrative expenses were a key factor in reducing the Adjusted Operating Expense to $62 million, down from $69 million in Q2 2025. This reduction in SG&A helped drive the Adjusted Operating Margin for Q3 2025 to 5.5% for continuing operations. The global sales force supports the Sample Management Solutions and Multiomics segments across North America, Europe, and Asia.

Operating costs for global biorepository and cold-chain infrastructure are embedded within COGS and operating expenses, reflecting the complexity of maintaining reliable cold-chain custody. The Sample Management Solutions segment revenue, which includes these services, was $78 million in Q3 2025. The company's commitment to this infrastructure is a fixed cost component that underpins the value proposition of sample integrity. Capital expenditures for the full fiscal year 2024 were approximately $38 million, indicating ongoing investment in these physical assets.

Restructuring and portfolio simplification costs (e.g., B Medical sale) have been a notable, though temporary, cost factor. The intention to sell the B Medical Systems segment was announced in fiscal Q1 2025, leading to its classification as a discontinued operation. In Q2 2025, the company noted increased restructuring and transformation charges. However, by Q3 2025, GAAP Operating Expenses reflected lower restructuring charges year-over-year. These charges are adjustments not representative of normal operations, but they impacted the GAAP results, contributing to the total diluted EPS loss of ($0.88) in Q2 2025, which included ($0.49) from discontinued operations.

Here's a quick look at the latest reported operational expense snapshot for continuing operations (Q3 2025):

Metric (Continuing Operations)	Q3 2025 (USD Millions)	Change vs. Q2 2025	Change vs. Q3 2024
Revenue	144	0%	0%
Adjusted Operating Expense	62	Down 10.1%	Down 4%
Adjusted Operating Margin	5.5%	+150 basis points	+340 basis points

The overall financial impact of the 2025 fiscal year, ending September 30, 2025, showed a total Net Loss attributable to common shareholders of -$59.50 million, which was a significant improvement from the -$164 million loss in fiscal year 2024. This reflects the cost discipline applied across the core business as the divestiture process moved forward.

• Total FY 2025 Revenue (All Operations): $593.82 million.
• FY 2024 Total Revenue: $656.32 million.
• Cash, cash equivalents, restricted cash and marketable securities as of March 31, 2025: $540 million.
• FY 2025 Organic Revenue Growth Guidance (Reiterated): Range of 3% to 5% relative to fiscal 2024.

Finance: draft 13-week cash view by Friday.

Azenta, Inc. (AZTA) - Canvas Business Model: Revenue Streams

You're looking at how Azenta, Inc. (AZTA) converts its core life science services into actual dollars as of late 2025. It's all about the two main pillars now that they've streamlined the portfolio. Here's the quick math on where the money came from in fiscal year 2025 (FY25).

The overall picture for FY25 showed reported revenue of $594 million, marking a 4% increase year-over-year from continuing operations. This top-line performance resulted in a Non-GAAP Diluted EPS for the full fiscal year 2025 of $0.51.

The revenue streams are clearly segmented across their two primary business units. You can see the split below:

Revenue Stream Segment	FY25 Reported Revenue (in millions)	Year-over-Year Reported Growth	FY25 Non-GAAP Gross Margin
Sample Management Solutions (SMS)	$325 million	2%	49.3% (Q4'25 SMS Non-GAAP Gross Margin)
Multiomics	$269 million	6%	Not explicitly stated for full year, Q4'25 Non-GAAP Gross Margin was 46.7% (Total)

The Multiomics segment was the primary driver of the overall revenue increase for the full year, showing 6% growth, while SMS grew 2%.

Drilling down into the specifics of how these segments generate revenue, you see a mix of service contracts, product sales, and recurring consumables revenue. For the Multiomics business, the revenue streams are heavily weighted toward high-throughput genomic services:

• Multiomics services revenue: Includes gene sequencing, synthesis, and analysis.
• Next-Generation Sequencing (NGS) services showed impressive momentum, with volume rising 50% year-over-year in the fourth quarter.
• Multiomics delivered record revenue of $73 million in the fourth quarter of 2025.

The Sample Management Solutions revenue stream is more diverse, incorporating both capital equipment sales and ongoing service/consumable revenue. This is where you find the sales of automated storage systems and cryogenic freezers, alongside the critical recurring components.

Recurring revenue from Sample Repository Services (SRS) and consumables is a key component here, providing a more predictable base. Specifically, growth in Clinical Biostores, Consumables and Instruments, and Sample Storage were cited as drivers for the SMS segment in FY25. To be fair, revenue from Cryogenic Systems and Automated Stores was lower in the fourth quarter, but other core products offset that decline.

Here are the key revenue drivers within the SMS segment as reported for the fourth quarter:

• Recurring revenue from Sample Repository Services (SRS).
• Sales of consumables and instruments.
• Revenue from Clinical Biostores.
• Sales of automated storage systems and cryogenic freezers (though Cryogenic Systems revenue was lower in Q4'25).

Finance: draft 13-week cash view by Friday.